What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection CNNWeight loss drug could reduce heart attack risk by 20%, study finds The GuardianWegovy weight loss sustained for four years in trial, Novo Nordisk says ReutersLong-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature.comWegovy (NVO) Cut Risk of Heart Attack, Stroke No Matter Weight Lost Bloomberg